3Drusano GL, Preston SL, Hardalo C.Use of preclinical data for se- lection of a phase II/III dose for evemimicin and identification of a preclinical MIC breakpoint[J].Antimicrob Agents Chemother,2001, 45(1): 13.
4Perry TR,Schentag JJ.Clinicaluse of ceftriaxone:a pharmacokinetic- pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding[J].Clin Pharmacokinet, 2001,40(9):685.
5Lodise TJ, Lomaestro B, Rodvold KA, et al.Pharmacodynamic profil- ing of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simu- lation[J].Antimicrob Agents Chemother, 2004,48(12) :4718.
6Mouton JW, Dudley MN,Cars O,et al.Standardization of pharmacoki- netic/pharmacodynamic(PK/PD) terminology for antiinfective drugs: an update[J].J Antimicrob Chemother,2005,55(5):601.
7Frei CR,Wiederhold NP,Burgess DS.Antimicrobial breakpoints for gram- negative aerobic bacteria based on pharmacokinetic-phar- macodynamic models with Monte Carlo simulation[J].JAC ,2008,61 (3) : 621.
8Nakamura T, Shimizu C, Kasahara M, et al.Monte Carlo simulation for evaluation of the efficacy of carbapenems and new.quinolones against ESBL-prodncing Escherichia coli.[J].J Infect Chemother, 2009,15(1):13.
9Mikamo H ,Tanaka K ,Watanabe K.Prediction on the efficacy of flu- oroquinolones for anaerobic infections using Monte Carlo simulation[J]. Jpn J Antibiot,2007,60(6) : 335.
10MOUTON JW, DUDLEY MN, CARS O, et al. Standardization of pharmacokinetic/pharmacodynamic(PK/PD) terminology for anti- infective drugs: an update [ J]. J Antimicrob Chemother, 2005,55 (5) :601 -607.
